Asymmetric Investing by Travis Hoium on $HIMS (Nov 10, 2026)
HIMS fell 18% after a disappointing quarter: subscribers fell about 100,000 QoQ, gross margin dropped from 83% to 57% on branded GLP-1 mix, Q4 revenue is guided slightly down and full-year adjusted EBIT guidance was cut. The speaker is not selling and still calls HIMS a great company to own over 5-10 years, based on its higher-priced subscription, TRT and peptide strategy and Costco-like health-subscription model, with management betting on Q1 2027; short-term subscriber growth and competition leave questions, and next quarter's guidance is important.
Playing via YouTube may share device and playback data and use cookies. Privacy Notice · Google Privacy Policy
Jump to any passage
Shares of his and hers are down 18% in late trading on Tuesday after their company reported earnings on Monday. The investors did not like what they heard from the earnings report.
In a lot of ways, the report was really disappointing. The number of subscribers was down quarter over quarter. Gross margins continued to be under pressure. And management said that they were actually not spending as much to bring in those new customers. That's why growth really slowed.
They also did not talk about their 2030 guidance, something that they've done consistently in the past. But long-term, this may actually make sense. It's going to take a while to figure out if management is doing the right things here.
They brought Andrew Huberman on to the be on the board of directors, also going to be an adviser to the company. So, he's probably going to be a big push into peptides.
And let's dig right into the position that was number one in my portfolio going into the day yesterday. That's Hims and Hers. Now down to number four after a pretty big jump from Zeta Global.
Cover them on the channel later on today. Hims and Hers, like I said, shares down 18% and over the past month, shares are down about 40%. So really, really bad performance on the stock market recently for him and hers.
We're going to start with revenue because revenue was up 49% from a year ago. That would normally be a really good thing, but a lot of this revenue is coming from their eucalyptus acquisition.
So that's the reason revenue was up like it was in the quarter.
Management also guid guided for reven revenue to be down a little bit in the fourth quarter. Gross margin, gross profit margin from a percentage standpoint is down sharply. Used to be in this 83% range.
That was when they were selling a lot of generic products, a lot of compounded products. Now that's down to 57%.
The reason is they're selling a lot more branded GLP1s. So they've made deals with Novo Nordisk. They've made made a deal recently with Eli Liy. We're going to see pressure on the margin side.
The good news though, and don't forget this, is that the gross margin dollars continue to go up. So, the amount of actual dollars in gross profit that Hims and Hers is making continues to go up despite the fact that sequentially the number of subscribers on the platform was actually down.
This is the operating profit. So, the operating operating margin was negative about 13% over the past two quarters. Got a little bit better this quarter. There are a number of different factors for that.
They did have positive adjusted EBIT. once you adjust some of the one-time costs out. They've had a lot of stockbased compensation for hiring a lot of people. So, that's driving some of these losses here, but definitely something to keep an eye on.
Now, I'm not super worried about operating profit. I actually want this to be slightly positive. Don't like that it's negative, but again, another thing that investors are worried about.
Now, the biggest negative, if you're going to take any negative from the quarter, it has to be this number right here. This is the number of subscribers for him and hers. and it was down about a 100,000 subscribers in the third quarter versus the second quarter.
So the number of people paying him and hers each quarter is actually going down.
Now the context for that is the blue line here which is the monthly revenue per average subscriber. So the monthly revenue per subscriber continues to go up. What is the reason for this?
The reason is that Hims and Hers has moved away from some of the lowcost products that they've really grown up on, ED, hair loss, things that maybe are $20 a month, $30 a month, and they moved into more of these higher price items like GLP1s where you're talking about a starting point of $300 per month.
The other thing that they've done is moved to higher price point for even those products. So, if you look back to when they were selling a lot of compounded GLP ones, you could get those for $150 per month.
Now, it's $150 per month from a starting point for the GLP1 itself, for the prescription itself. And on top of that, you pay for a membership. So, there's two pieces of this. This is the reason that people are spending more on the subscriptions that they have to hims and hers.
So, what the company is clearly doing is moving away from those lower cost subscriptions and more towards these higher cost subscriptions. The trade-off is you just simply have less people subscribed to the platform.
Management also said that they've been spending less on sales and marketing recently, pulling back on some of that as they prepare for some of their new products that are going to be coming out later this year and then into 2027.
So, you actually see that in the numbers right here on the left in purple. Selling general and administrative expenses. That was down nearly $20 million quarter over quarter. So, we're seeing that in the numbers.
They're also spending a lot more money on R&D. So, building out their AI capabilities and things like that. This is stuff that management said is more engaging on the platform, but we're not quite seeing that in people actually subscribing more to the platform.
So, there's kind of a push and pull here in the story that what's going on with him and hers. The company's not growing the way that you would maybe like.
Management said, "You know what? It's gotten really competitive out there in the GLP1 space. We want maybe want to save some of our money from some of these new products that are coming out like TRT, like peptides, and we want to go big in the early part of 2027 when that's when people are really primed to be losing weight, set their goals for 2027.
That's when we see a bigger opportunity." That's the story that they were telling on the conference call.
This is TRT, which they just announced a couple of weeks ago. So, this has come to him and hers. We've seen some advertising for this already. So, we're starting to see that with football, something that they said they are going to advertise more.
Expect to see that maybe in the NFL playoffs early in 2027.
Again, this is going to line up with when people are saying, you know, maybe I want to lose lose a little bit of weight after the holidays. They're looking for those kind of solutions.
Himson and Hers has said, "Hey, we want to be the solution for people at that period of time."
The price point here, you're going to get a $50 membership. Again, this is kind of the trend that Hims and Hers is moving toward is different memberships. $150 for weight loss membership, $50 for a TRT membership, and then prescriptions start at $50 a month, go all the way up to $180 a month.
The bigger thing in 2027, and they actually said this is going to be launching later this month, is peptides. So, peptides are going to be coming to the platform. Not all of them are going to be be available.
In particular, BBC57 is not going to be be available initially, at least that's their current plan.
But the big differentiator for him and hers is that they are going to be making a lot of this in-house. So they said that on the conference call. So later this month, Samarellan, gluion, and NAD plus are going to be a available on the platform.
BBC157 and TB500 are going to be coming a little bit later. They're also going to be making the raw APIs in Menllo Park. So in their internal facility, so these are going to be 100% produced in the US.
I think that's going to ultimately be a pretty big differentiator for him and hers when it comes to the peptides business. But how big is that going to be? How fast is it going to scale both in 2026 and then into 2027?
That's something that we don't really know right now.
So what management is saying is, hey, we pulled back on growth that we could have gone out and acquired in the third quarter and early into the fourth quarter because we think that there's bigger opportunities to acquire those customers that are going to be long-term big values in early 2027.
And the driver there from a prescription standpoint is going to be TRTs and peptides.
To that end, Dr. Andrew Huberman also announced that he is going to be joining the board of directors and is going to be an adviser for the company. So again, are you looking at him and hers short-term or are you looking at it long term?
Short-term, there's definitely pressures on the company. I don't like that they aren't growing the number of subscribers.
Here's a look at their revenue guidance for the fourth quarter of 2026. You can see that that's likely to be down slightly from the third quarter. Their adjusted EBITDO margin not all that impressive at 8 to 10%. and for the full year they actually reduced their adjusted EBIT dot guidance.
So there's a lot of questions short-term is is this strategy working but what I continue to go back to is I think him and hers has the right view of where this industry is going long term.
So they talked a lot on the conference call about being the place where people's data ends up. So this is labs this is the wearables that you have every day. There was a question about wearables and management effectively said, "Hey, you know, wherever you have a wearable, we want to have that data on him and hers, but they're also going to be providing those wearables eventually as part of subscriptions."
I think that's where the business is ultimately headed is this is going to be a subscription business, a subscription health business. And then the actual prescriptions that you get and other things that you're paying for are going to be relatively low margin.
It's going to be a little bit like a Costco model where the membership itself is where Costco makes the profit. everything else is effectively sold at cost.
That could ultimately be really disruptive because it's impossible for competitors to compete with that once you start to build out a subscription that has multiple pieces to it where you're getting value from multiple pieces.
I think that's a reasonable long-term strategy, but that's not going to help the numbers in the third quarter, in the fourth quarter. Something that's going to take time to play out.
They're also making a big bet on the future on some of these new products that are coming, in particular, peptides, and that could be really risky for the company.
But I want to go back to where they started the earnings letter. And I also want to note that they did not have an earnings presentation. So they've done presentations that have been pretty consistent over the past number of quarters.
I can't even go back to when they didn't do that similar presentation. They did not have that in this quarter. That was another sort of red flag for me. When management starts to present different things is telling you that the story is changing.
But I do like this line right here. In healthcare, whoever owns the customer relationship wins. And that's exactly what we're building with Hims and Hers. And this comes down to people having real choice and real value in what they're getting from their doctor and from their prescriptions.
I think that's the kind of platform that Hims and Hers is building, but these are there are bumps along the road. This is definitely one of those bumps.
I'm not selling my shares in Hims and Hers, but this is one of those quarters that kind of makes you question, is this going to be a hyper competitive space? Is the competition that we get from Row, from Amazon, from all kinds of other small players, is that going to be too much to handle to have a big profitable business long term?
Management has to answer those questions over the next handful of quarters. What they're clearly stating is that they're putting a lot of eggs in the Q1 2027 basket. So, we'll see what they say on the next conference call.
By then, we're by then we're going to know what peptides look like from both a pricing standpoint and a volume standpoint. They're going to know what those numbers start to look like.
So actually the guidance next quarter is going to be really really important because it's going to tell you when they get back into this customer acquisition zone are they going to be able to do that profitably and grow profitably as a business.
Lots of questions for him and hers. I think you look 5 10 years out if you have that long-term horizon. This is still a great company to own. But there are reasons not to like this current quarter.
Watchpoints
What this channel has said about $HIMS
Asymmetric Investing by Travis Hoium has 5 calls on this stock; only the adjacent ones are shown.